CDT1 has been implicated in various types of cancer due to its role in maintaining genomic stability. Overexpression or misregulation of CDT1 can contribute to the uncontrolled cell proliferation characteristic of cancer. Studies have shown that CDT1 is often overexpressed in several cancers, including breast, lung, and colorectal cancers. As a result, CDT1 is considered a potential target for cancer therapy. Inhibitors of CDT1 or its interaction with geminin are being explored as potential therapeutic strategies.
